STOCK TITAN

Zynex, Inc. Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Zynex, Inc. has engaged MZ Group to lead their strategic investor relations and financial communications program. MZ will work with Zynex to increase the company's visibility and deliver the investment opportunity to a broader audience.
Positive
  • Zynex has engaged MZ Group to lead their investor relations program, which could increase the company's visibility and attract more investors.
  • MZ Group has a distinguished reputation as a premier resource for institutional investors and private investors, which could attract more investors to Zynex.
Negative
  • None.

ENGLEWOOD, Colo., July 10, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has engaged international investor relations specialists MZ Group ("MZ") to lead their comprehensive strategic investor relations and financial communications program across all key markets.

MZ Group will work closely with ZYXI's management to build upon their investor relations and shareholder communication program designed to increase the Company's visibility throughout the investment community.

Quinn Callanan, CFA, Senior Vice President at MZ North America, will assist ZYXI in all corporate and financial communications facets, including coordinating investment conferences across key cities and building brand awareness with financial media outlets. MZ has developed a distinguished reputation as a premier resource for institutional investors, brokers, analysts, and private investors.

Mr. Callanan stated, "We at MZ are eager to work with Zynex to help them achieve their mission of improving the quality of life for patients in pain. Zynex operates in an exciting market with substantial growth opportunities. The company has a track record of revenue growth while maintaining gross margins similar to SaaS companies. We believe there is a fundamental valuation gap, and we're looking forward to working with the management team to deliver the investment opportunity to a broader audience."

Thomas Sandgaard, President and CEO of Zynex, stated, "Zynex is focused on delivering shareholder value by continuing the profitable growth in its of pain management division and developing and selling the next generation of patient monitoring equipment. We believe that having MZ as a partner will assist in this goal by broadening our reach within the investment community and achieving a fair valuation. We look forward to working with Quinn and the entire team at MZ Group to communicate the multiple avenues to drive growth and building long-term value for our shareholders."

About MZ Group

MZ North America is the US division of MZ Group, a global leader in investor relations and corporate communications. MZ North America was founded in 1996 and provides full scale Investor Relations to both private and public companies across all industries. Supported by our exclusive one–stop–shop approach, MZ works with top management to support the clients' business strategy in six integrated product and service categories: 1) IR Consulting & Outreach – full service investor relations and roadshow services; 2) ESG iQ & Advisory – reporting technology platform and audit and reporting guidance; 3) SPAC Alpha IR+ & IPO Advisory – providing critical and timely guidance through business combinations and IPOs; 4) Financial & Social Media – lead generation and social media relations; 5) Market Intelligence – real time ownership monitoring; 6) Technology Solutions – webhosting, webcasting, conference calls, distribution services and board portals. MZ North America has a global footprint with offices located in New York, Chicago, San Diego, Aliso Viejo, Austin, Minneapolis, Taipei and São Paulo.

About Zynex, Inc.

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

MZ Contact
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
ZYXI@mzgroup.us
+949 694 9594

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-inc-engages-mz-group-to-lead-strategic-investor-relations-and-shareholder-communication-program-301872422.html

SOURCE Zynex

FAQ

What is Zynex, Inc. engaging MZ Group for?

Zynex, Inc. has engaged MZ Group to lead their strategic investor relations and financial communications program.

What is the goal of Zynex in engaging MZ Group?

The goal is to increase the company's visibility and deliver the investment opportunity to a broader audience.

What is MZ Group's reputation?

MZ Group has a distinguished reputation as a premier resource for institutional investors and private investors.

Zynex, Inc.

NASDAQ:ZYXI

ZYXI Rankings

ZYXI Latest News

ZYXI Stock Data

345.71M
15.72M
51.14%
31.25%
18%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
ENGLEWOOD

About ZYXI

zynex, inc. founded in 1996, engineers, manufactures and markets neuro-diagnostics, stroke rehabilitation, pain management and cardiac monitoring devices within three subsidiaries. zynex medical is a provider of electrotherapy products for home use. zynex monitoring solutions develops products for cardiac monitoring for use in hospitals. zynex neurodiagnostics develops devices for emg and eeg diagnostic applications within neurology disciplines. zynex medical's product line is fully developed, fda/ce cleared, commercially sold, and has been developed to uphold the company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. zynex monitoring solutions and zynex neurodiagnostics are currently both in the development stages without any significant revenues.